Metraipolis › archive › dc_b2ff76103d6c

Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma — Europe PMC PMID:41878443

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41878443
DOI
10.3389/fimmu.2026.1715761
License (as archived)
solo-consultazione
Archived
2026-11-05T00:12:53.422Z
SHA-256 of the archived text
8f59ddf9d592f0861a61603f732bc814903dce6d29a07ef9b582a2a7fd3b38b3
Stable URL of this page
https://metraipolis.com/documento/dc_b2ff76103d6c

How to cite

Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma — Europe PMC PMID:41878443 — Europe PMC (en), https://europepmc.org/article/MED/41878443 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b2ff76103d6c (Metraipolis archive dc_b2ff76103d6c, sha256 8f59ddf9d592f0861a61603f732bc814903dce6d29a07ef9b582a2a7fd3b38b3)
BibTeX
@misc{dcb2ff76103d6c,
  title = {Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma — Europe PMC PMID:41878443},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41878443},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b2ff76103d6c; sha256 8f59ddf9d592f0861a61603f732bc814903dce6d29a07ef9b582a2a7fd3b38b3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41878443. Agents can read the archived copy with the MCP tool read_document.